Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Drug Reaction
100%
Adverse Event
94%
Disproportionality Analysis
75%
Aprepitant
71%
Antiemetic Agent
67%
Malignant Neoplasm
60%
Granisetron
50%
Chemotherapy
47%
Bendamustine
47%
Adverse Event
44%
Pharmacotherapy
35%
Hematologic Malignancy
31%
Dexamethasone
31%
Chemotherapy Induced Nausea and Vomiting
31%
Palonosetron
30%
Paclitaxel
29%
Polypharmacy
29%
Community Pharmacy
29%
Malignant Neoplasm
29%
Omeprazole
25%
Bortezomib
24%
Carfilzomib
24%
Oxaliplatin
24%
Pharmacokinetic
21%
Congestive Heart Failure
21%
Naldemedine
20%
Advanced Cancer
20%
Narcotic Analgesic Agent
20%
Cancer Pain
19%
Lenalidomide
19%
Ixazomib
19%
Cyclophosphamide
18%
Analgesic Agent
17%
Proteasome Inhibitor
17%
Drug
16%
Irradiation
16%
Cancer Chemotherapy
16%
Nivolumab
16%
Proton Pump Inhibitor
16%
Idarubicin
16%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
16%
Constipation
16%
Rodent
16%
Capecitabine
16%
Juvenile Rheumatoid Arthritis
16%
Hand Foot Syndrome
16%
Pharmacology
16%
Narcotic Agent
16%
Hypocalcemia
16%
Bortezomib
16%
Medicine and Dentistry
Adverse Event
66%
Bendamustine
32%
Patient
30%
Proton-Pump Inhibitor
27%
Allogeneic Hematopoietic Stem Cell Transplantation
25%
Febrile Neutropenia
18%
Odds Ratio
16%
Non Small Cell Lung Cancer
16%
Whole Body Radiation
16%
Tacrolimus
16%
Hand Foot Syndrome
16%
Capecitabine
16%
Bortezomib
16%
Aprepitant
16%
Low Drug Dose
16%
Drug Therapy
16%
Pediatrics
16%
Mycophenolate Mofetil
16%
Mechanical Allodynia
16%
Kidney Graft
16%
Cyclophosphamide
16%
Observational Study
16%
Docetaxel
16%
Kidney Function
16%
FDA Adverse Event Reporting System
16%
Antibody-Drug Conjugate
16%
Association
15%
Analysis
14%
Neuropathy
13%
Oxaliplatin
13%
Paclitaxel
13%
Chemotherapy
13%
Odds Ratio
13%
Oral Drug Administration
12%
Dermatosis
10%
Cold Hyperalgesia
10%
Adverse Drug Reaction
10%
Oncology
10%
Biguanide
9%
Symptom
9%
Platelet
9%
Omeprazole
9%
Acute Graft Versus Host Disease
9%
Duloxetine
8%
Cytomegalovirus Infection
8%
Peripheral Neuropathy
8%
Malignant Neoplasm
8%
Bone Marrow Suppression
8%
Intravenous Drug Administration
7%
Polatuzumab Vedotin
7%
